Skip to main content

Table 1 Baseline characteristics, all patients

From: Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life

  All patients (N = 521)
Age  
Years, median (range) 66.3 (39-86)
≥ 70 years, n (%) 188 (36.1)
Gender, n (%) male 363 (69.7)
Origin, n (%) Caucasian 514 (98.7)
Weight, kg [mean (SD)] 74.9 (14.45)
Smoking status, n (%)  
Current smoker 139 (26.7)
Ex-smoker 243 (46.6)
Never smoked 138 (26.5)
Missing data 1 ( 0.2)
Histology, n (%)  
Non-squamous cell carcinoma 444 (85.2)
Squamous cell carcinoma a 77 (14.8)
Disease stage at study entry, n (%)  
Stage IIIa 35 ( 6.7)
Stage IIIb 103 (19.8)
Stage IV 383 (73.5)
  All patients (N = 521)
Karnofsky Index (KI), n (%)  
KI ≥ 80% 323 (62.0)
KI 70% 134 (25.7)
KI 60% 45 ( 8.6)
KI 50% 18 ( 3.5)
Missing data 1 ( 0.2)
Type of previous first-line chemotherapy  
Platinum-based combinations, n (%) 450 (86.4)
Platinum-free combinations, n (%) 12 ( 2.3)
Single-agent, n (%) 59 (11.3)
Most frequent agents used (at least 10% of patients), n (%)b  
Carboplatin 327 (62.8)
Cisplatin 135 (25.9)
Vinorelbine 162 (31.1)
Gemcitabine 159 (30.5)
Paclitaxel 131 (25.1)
Duration of previous first-line chemotherapy, months [median (range)] 3.5 (0-32)
Time elapsed since previous first-line chemotherapy, months [median (range)] 3.9 (0-74)
Patients [n (%)] who started pemetrexed  
Immediately after end of first-line treatmentc 82 (15.7)
Within 3 months after end of first-line treatmentd 132 (25.3)
More than 3 months after end of first-line treatmente 302 (58.0)
Missing data 5 (1.0)
  1. N = total number of patients, n = number of patients, SD standard deviation
  2. a) The study started in 2007, before the label change in April 2008 which restricted the use of pemetrexed to patients with non-squamous cell carcinoma
  3. b) Multiple nominations possible
  4. c) First dose of pemetrexed given ≤ 28 days after the last dose of first-line therapy
  5. d) First dose of pemetrexed dose given > 28 days but ≤ 3 months after the last dose of first-lintherapy
  6. e) First dose of pemetrexed dose given > 3 months after the last dose of first-line therapy
\